Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251026 · ClinicalTrials.gov registry record · Phase 1
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
A Phase 1 study of Mucopolysaccharidosis II, sponsored by Denali Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 7
- Study locations
NCT04251026 is a Phase 1 study of Mucopolysaccharidosis II that is active but no longer recruiting, run by Denali Therapeutics. The registered enrollment target is 47 participants, below the 67-participant average among 7 other Mucopolysaccharidosis II trials with a reported enrollment target (30% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT04251026, a Phase 1 study of Mucopolysaccharidosis II, is active but no longer recruiting, sponsored by Denali Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome). Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.
Conditions Studied
Interventions
- DRUG tividenofusp alfa
Study Locations (7)
California
- UCSF Benioff Children's Hospital - Oakland
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
North Carolina
- UNC Children's Research Institute - Chapel Hill
Pennsylvania
- UPMC | Children's Hospital of Pittsburgh - Pittsburgh
Quebec
- McGill University Health Centre - Royal Victoria Hospital - Montreal
South Holland
- Erasmus Medical Center - Rotterdam
Other
- St Mary's Hospital, Manchester Academic Health Science Centre - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2031-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04251026
The ClinicalTrials.gov registry entry for NCT04251026 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 7 other Mucopolysaccharidosis II trials with a reported enrollment target (30% lower). The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucopolysaccharidosis II appearing as the primary indexed condition, and to 1 intervention - of which tividenofusp alfa is the first listed.
NCT04251026 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04251026 about?
NCT04251026 is a clinical study titled "A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome". This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manif...
What is the current status of trial NCT04251026?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-07-16. Estimated completion is 2031-02.
What conditions does trial NCT04251026 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis II.
What interventions are being tested in trial NCT04251026?
The interventions under investigation include: tividenofusp alfa (DRUG).
Who is sponsoring clinical trial NCT04251026?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04251026 being conducted?
This trial has 7 study locations across California, Illinois, North Carolina, Pennsylvania, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucopolysaccharidosis II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
ACTIVE NOT RECRUITING · Phase 1
-
Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)
COMPLETED · Phase 1
-
Registry of Patients Diagnosed With Lysosomal Storage Diseases
RECRUITING
-
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
RECRUITING · Phase 2
-
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.